The bigger trial said no. Then the paper was flagged.
A large trial of exenatide — the GLP-1 drug the field had pinned real hope on — found no benefit in Parkinson's. Eighteen months later the paper was placed under an expression of concern after inspectors found serious problems at one of its hospitals. Both facts matter.
Study: The Lancet